A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen. [PDF]
PLoS ONE, 2015 In the HIV vaccine field, there is a need to produce highly immunogenic forms of the Env protein with the capacity to trigger broad B and T-cell responses.
Aneesh Vijayan +8 more
doaj +1 more source
Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy [PDF]
, 2007 The successful use of small interfering RNAs (siRNAs) for therapeutic purposes requires safe and efficient delivery to specific cells and tissues. Here we demonstrate cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer. The
Haitang Li +4 more
core +2 more sources
eLife, 2015 The HIV-1 envelope protein gp120 is both the target of neutralizing antibodies and a major focus of vaccine efforts; however how it is delivered to B cells to elicit an antibody response is unknown.
Chung Park +3 more
doaj +1 more source
HIV-1 gp120 influences the expression of microRNAs in human monocyte-derived dendritic cells via STAT3 activation [PDF]
, 2015 Background: MicroRNAs (miRs) are an abundant class of small non-coding RNAs (~22 nt) that reprogram gene ex- pression by targeting mRNA degradation and translational disruption.
Da Sacco, Letizia +5 more
core +1 more source
Specific HIV gp120-cleaving Antibodies Induced by Covalently Reactive Analog of gp120 [PDF]
Journal of Biological Chemistry, 2003 We report the results of efforts to strengthen and direct the natural nucleophilic activity of antibodies (Abs) for the purpose of specific cleavage of the human immunodeficiency virus-1 coat protein gp120. Phosphonate diester groups previously reported to form a covalent bond with the active site nucleophile of serine proteases (Paul, S., Tramontano ...
Sudhir, Paul +7 more
openaire +2 more sources
HIV-1gp120 induces neuronal apoptosis through enhancement of 4-aminopyridine-senstive outward K+ currents. [PDF]
PLoS ONE, 2011 Human immunodeficiency virus type 1 (HIV-1)-associated dementia (HAD) usually occurs late in the course of HIV-1 infection and the mechanisms underlying HAD pathogenesis are not well understood. Accumulating evidence indicates that neuronal voltage-gated
Lina Chen +5 more
doaj +1 more source
Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco [PDF]
, 2014 The proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV-1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most ...
EMEA +4 more
core +1 more source
Blood-Brain Barrier Abnormalities Caused by HIV-1 gp120: Mechanistic and Therapeutic Implications
The Scientific World Journal, 2012 The blood-brain barrier (BBB) is compromised in many systemic and CNS diseases, including HIV-1 infection of the brain. We studied BBB disruption caused by HIV-1 envelope glycoprotein 120 (gp120) as a model.
Jean-Pierre Louboutin, David S. Strayer
doaj +1 more source
Molecular evolution of HIV-1 CRF01_AE Env in Thai patients. [PDF]
PLoS ONE, 2011 BACKGROUND: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1.
Samatchaya Boonchawalit +11 more
doaj +1 more source
Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120
Beilstein Journal of Organic Chemistry, 2012 Based on the structure of the HIV-1 glycoprotein gp120 in complex with its cellular receptor CD4, we have designed and synthesized peptides that mimic the binding site of CD4 for gp120.
Julia Meier +3 more
doaj +1 more source